Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 26, Issue 8, Pages 1589-1604
Publisher
Oxford University Press (OUP)
Online
2015-06-04
DOI
10.1093/annonc/mdv257
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Enzalutamide After Docetaxel and Abiraterone Acetate Treatment in Prostate Cancer: A Pooled Analysis of 10 Case Series
- (2015) Fausto Petrelli et al. Clinical Genitourinary Cancer
- PSA Flare With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2015) Salvatore L. Burgio et al. Clinical Genitourinary Cancer
- PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
- (2015) Roberta Ferraldeschi et al. EUROPEAN UROLOGY
- Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer
- (2015) Eleni Efstathiou et al. EUROPEAN UROLOGY
- Metastasis-directed Therapy of Regional and Distant Recurrences After Curative Treatment of Prostate Cancer: A Systematic Review of the Literature
- (2015) Piet Ost et al. EUROPEAN UROLOGY
- Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)
- (2015) Nicholas David James et al. EUROPEAN UROLOGY
- Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results
- (2015) Michael J. Morris et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
- (2015) H H Cheng et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Aggressive Variants of Castration-Resistant Prostate Cancer
- (2014) H. Beltran et al. CLINICAL CANCER RESEARCH
- Activity of Cabazitaxel After Docetaxel and Abiraterone Acetate Therapy in Patients With Castration-Resistant Prostate Cancer
- (2014) Avishay Sella et al. Clinical Genitourinary Cancer
- Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: A review and position statement by the European Organisation for Research and Treatment of Cancer imaging group
- (2014) F.E. Lecouvet et al. EUROPEAN JOURNAL OF CANCER
- Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer
- (2014) Antoine Angelergues et al. EUROPEAN JOURNAL OF CANCER
- Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)
- (2014) Matthew R. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapy monitoring of skeletal metastases with whole-body diffusion MRI
- (2014) Anwar R. Padhani et al. JOURNAL OF MAGNETIC RESONANCE IMAGING
- Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial
- (2014) Karim Fizazi et al. LANCET ONCOLOGY
- Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
- (2014) Oliver Sartor et al. LANCET ONCOLOGY
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of Treatment Response by Total Tumor Volume and Global Apparent Diffusion Coefficient Using Diffusion-Weighted MRI in Patients with Metastatic Bone Disease: A Feasibility Study
- (2014) Matthew D. Blackledge et al. PLoS One
- Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone
- (2014) Daniel L. Suzman et al. PROSTATE
- Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis
- (2014) Guohua Shen et al. SKELETAL RADIOLOGY
- Long-term Tolerability and Efficacy of Degarelix: 5-Year Results From a Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix
- (2014) E. David Crawford et al. UROLOGY
- Challenges and Recommendations for Early Identification of Metastatic Disease in Prostate Cancer
- (2014) E. David Crawford et al. UROLOGY
- Multiparametric MRI for Recurrent Prostate Cancer Post Radical Prostatectomy and Postradiation Therapy
- (2014) Flavio Barchetti et al. Biomed Research International
- Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
- (2013) Y. Loriot et al. ANNALS OF ONCOLOGY
- Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
- (2013) K. L. Noonan et al. ANNALS OF ONCOLOGY
- Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy
- (2013) M. T. Schweizer et al. ANNALS OF ONCOLOGY
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
- (2013) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [18F]choline positron emission tomography(PET)/computed tomography (CT) and [18F]NaF PET/CT
- (2013) Mads H. Poulsen et al. BJU INTERNATIONAL
- The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer
- (2013) Rahul Aggarwal et al. CANCER
- Choline PET or PET/CT and Biochemical Relapse of Prostate Cancer
- (2013) Laura Evangelista et al. CLINICAL NUCLEAR MEDICINE
- Role of Magnetic Resonance Imaging in the Detection of Local Prostate Cancer Recurrence after External Beam Radiotherapy and Radical Prostatectomy
- (2013) L.M. Wu et al. CLINICAL ONCOLOGY
- MRI for response assessment in metastatic bone disease
- (2013) F. E. Lecouvet et al. EUROPEAN RADIOLOGY
- Visceral Disease in Castration-resistant Prostate Cancer
- (2013) Carmel J. Pezaro et al. EUROPEAN UROLOGY
- Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents
- (2013) Carmel J. Pezaro et al. EUROPEAN UROLOGY
- Denosumab and Bone Metastasis–Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time
- (2013) Matthew R. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Prostate Cancer With Intermittent Versus Continuous Androgen Deprivation: A Systematic Review of Randomized Trials
- (2013) Saroj Niraula et al. JOURNAL OF CLINICAL ONCOLOGY
- Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
- (2013) Gwenaelle Gravis et al. LANCET ONCOLOGY
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer
- (2013) K Miller et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy
- (2013) E M Van Allen et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Bone Marrow Biopsy: RNA Isolation with Expression Profiling in Men with Metastatic Castration-resistant Prostate Cancer—Factors Affecting Diagnostic Success
- (2013) Charles E. Spritzer et al. RADIOLOGY
- Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
- (2012) J. Mezynski et al. ANNALS OF ONCOLOGY
- Can Whole-body Magnetic Resonance Imaging with Diffusion-weighted Imaging Replace Tc 99m Bone Scanning and Computed Tomography for Single-step Detection of Metastases in Patients with High-risk Prostate Cancer?
- (2012) Frédéric E. Lecouvet et al. EUROPEAN UROLOGY
- Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
- (2012) Christopher J Logothetis et al. LANCET ONCOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The CT flare response of metastatic bone disease in prostate cancer
- (2011) Christina Messiou et al. ACTA RADIOLOGICA
- Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response
- (2011) C. J. Ryan et al. CLINICAL CANCER RESEARCH
- Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer
- (2011) Andrew J. Armstrong et al. EUROPEAN UROLOGY
- Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone
- (2011) Eleni Efstathiou et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer
- (2011) E. David Crawford et al. JOURNAL OF UROLOGY
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- (2011) Karim Fizazi et al. LANCET
- Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
- (2011) Matthew R Smith et al. LANCET
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined androgen blockade with bicalutamide for advanced prostate cancer
- (2009) Hideyuki Akaza et al. CANCER
- The postchemotherapy PSA surge syndrome
- (2008) R. Thuret et al. ANNALS OF ONCOLOGY
- The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
- (2008) Laurence Klotz et al. BJU INTERNATIONAL
- Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer
- (2008) Joel B. Nelson et al. CANCER
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now